Study of whether treatment of congenital cytomegalovirus (cCMV) in infants who have experienced hearing-impairment reduces the loss in left or right ear hearing.
We are doing this study to compare the hearing and language outcomes of infants who receive 6 months of the investigational drug, valganciclovir, with children that do not receive valganciclovir. We also want to learn about safety and if there are any side effects of giving valganciclovir to infants with hearing loss caused by CMV
What we're hoping for
We are hoping to determine the most effective treatment for reducing the hearing loss in cCMV-infected infants.
ClinicalTrials.gov Identifier: NCT03107871